Sarepta Therapeutics Inc (SRPT): Two Viewpoints On The FDA News

Either way, I still like the long-term prospects for eteplirsen and Sarepta Therapeutics Inc (NASDAQ:SRPT). Of course, the timing of those prospects will surely be affected if accelerated approval doesn’t happen. However, the stock’s pullback could make a great opportunity to buy shares. Whether your view of Sarepta’s latest FDA news is positive or negative, the best view of all is a long-term one.

The article 2 Views on Sarepta’s FDA News originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.